1400 related articles for article (PubMed ID: 11397861)
21. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
22. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
23. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
24. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
25. Split daily recombinant human LH dose in hypogonadotrophic hypogonadism: a nonrandomized controlled pilot study.
Awwad JT; Farra C; Mitri F; Abdallah MA; Jaoudeh MA; Ghazeeri G
Reprod Biomed Online; 2013 Jan; 26(1):88-92. PubMed ID: 23177418
[TBL] [Abstract][Full Text] [Related]
26. Initiation of periovulatory events in primate follicles using recombinant and native human luteinizing hormone to mimic the midcycle gonadotropin surge.
Chandrasekher YA; Hutchison JS; Zelinski-Wooten MB; Hess DL; Wolf DP; Stouffer RL
J Clin Endocrinol Metab; 1994 Jul; 79(1):298-306. PubMed ID: 8027245
[TBL] [Abstract][Full Text] [Related]
27. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
28. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
Youssef MA; Al-Inany HG; Aboulghar M; Mansour R; Abou-Setta AM
Cochrane Database Syst Rev; 2011 Apr; (4):CD003719. PubMed ID: 21491386
[TBL] [Abstract][Full Text] [Related]
29. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety.
Ashrafi M; Kiani K; Ghasemi A; Rastegar F; Nabavi M
Arch Gynecol Obstet; 2011 Dec; 284(6):1431-8. PubMed ID: 21210134
[TBL] [Abstract][Full Text] [Related]
30. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
[TBL] [Abstract][Full Text] [Related]
31. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
33. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
34. Effect of recombinant human luteinizing hormone versus human chorionic gonadotrophin: effects on ovulation, embryo quality and transport, steroid balance and implantation in rabbits.
Romeu A; Molina I; Tresguerres JA; Pla M; Peinado JA
Hum Reprod; 1995 May; 10(5):1290-6. PubMed ID: 7657782
[TBL] [Abstract][Full Text] [Related]
35. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
36. Comparing the efficacy of urinary and recombinant hCG on oocyte/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial.
Madani T; Mohammadi Yeganeh L; Ezabadi Z; Hasani F; Chehrazi M
J Assist Reprod Genet; 2013 Feb; 30(2):239-45. PubMed ID: 23274511
[TBL] [Abstract][Full Text] [Related]
37. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
38. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
39. Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.
Christopoulos G; Vlismas A; Barsoum-Derias E; El-Shawarby S; Trew G; Lavery S
Hum Fertil (Camb); 2015; 18(4):248-52. PubMed ID: 26400626
[TBL] [Abstract][Full Text] [Related]
40. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction.
Balasch J; Creus M; Fábregues F; Civico S; Carmona F; Puerto B; Casamitjana R; Vanrell JA
J Assist Reprod Genet; 2001 May; 18(5):250-6. PubMed ID: 11464575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
